Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBT (2016 - 2025)

Arrowhead Pharmaceuticals' EBT history spans 16 years, with the latest figure at $28.3 million for Q4 2025.

  • For Q4 2025, EBT rose 116.14% year-over-year to $28.3 million; the TTM value through Dec 2025 reached $254.9 million, up 139.29%, while the annual FY2025 figure was $51.5 million, 108.41% up from the prior year.
  • EBT reached $28.3 million in Q4 2025 per ARWR's latest filing, down from $36.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $369.6 million in Q1 2025 to a low of -$179.1 million in Q2 2025.
  • Average EBT over 5 years is -$51.6 million, with a median of -$67.7 million recorded in 2021.
  • Peak YoY movement for EBT: tumbled 366.37% in 2024, then surged 391.05% in 2025.
  • A 5-year view of EBT shows it stood at -$62.9 million in 2021, then skyrocketed by 33.53% to -$41.8 million in 2022, then tumbled by 231.84% to -$138.7 million in 2023, then fell by 26.26% to -$175.1 million in 2024, then soared by 116.14% to $28.3 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's EBT are $28.3 million (Q4 2025), $36.1 million (Q3 2025), and -$179.1 million (Q2 2025).